199 Bay St, Suite 4000, Commerce Court West, Toronto, ON
Year called to bar: 1994 (ON)
Michael has more than 25 years of experience in banking and financial services law, with a particular specialization in corporate and commercial finance. His practice is focused on the areas of banking, syndicated lending, leveraged finance, project finance, and mergers & acquisitions. Michael regularly advises Canadian and foreign financial institutions and borrowers with respect to the structuring and negotiation of syndicated loan transactions, acquisition financings, takeover bid financings, leveraged buyouts, corporate reorganizations, workouts, and mergers & acquisitions. Michael is recognized as a leading lawyer in all major directories and publications.
As part of the transaction, an affiliate of OMERS subscribed for an aggregate of $30 million of Dye & Durham common shares, on a private placement basis
Digital Colony, the global digital infrastructure investment platform of Colony Capital, Inc., and a leading investor, owner and operator of companies enabling the next generation of mobile and Internet connectivity, acquired Beanfield Technologies Inc. (Beanfield)
Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, completed the recapitalization of approximately US$4 billion of secured and unsecured debt in September 2018 pursuant to a plan of arrangement (the “CBCA Plan”) under the Canada Business Corporations Act (“CBCA”).
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.
